Log in
pl
Reading room
About Terapia
For Authors
Contact
Reading room
Terapia January 2022
NR 1 ( 408 )
Clinical manifestations in long-COVID and post-COVID syndromes
Editor of the issue:
dr hab. n. med. Tomasz Dzieciątkowski
Contents:
Two years of SARS-CoV-2 menance
Authors:
dr hab. n. med. Tomasz Dzieciątkowski
Keywords:
telemedicine, primary health, coronavirus, pandemic
COVID-19 immunology – facts, doubts and challenges
Authors:
dr n. wet. Anna Golke
Keywords:
SARS-CoV-2, COVID-19, immune response, infection
Current recommendations for virological diagnosis of COVID-19, long-COVID and post-COVID syndromes
Authors:
dr hab. n. med. Tomasz Dzieciątkowski
Keywords:
SARS-CoV-2, COVID-19, laboratory diagnostics
Clinical manifestations of long-COVID syndrome in a pediatric population
Authors:
dr hab. n. med. Ernest Kuchar
Keywords:
coronavirus disease, COVID-19 complications, chronic fatigue syndrome, MIS-C, sequelae, post-COVID syndrome
Psychiatric aspects of the COVID-19 pandemic
Authors:
dr n. med. Piotr Wierzbiński
Keywords:
depression, COVID-19, stress, immunology
Long term respiratory effects of COVID-19
Authors:
prof. dr hab. n. med. Piotr Kuna
Keywords:
COVID-19, lungs, respiratory failure, post covid, long COVID, budesonide
Neurological complications in post-COVID syndrome
Authors:
lek. Stanisław Słyk
dr hab. n. med. Izabela Domitrz
Keywords:
post-COVID, long-COVID, SARS-CoV-2, neurological complications, coronavirus
COVID-19 and acute kidney injury
Authors:
prof. dr hab. n. med. Joanna Matuszkiewicz-Rowińska
prof. dr hab. n. med. Jolanta Małyszko
Keywords:
COVID-19, SARS-CoV-2, acute kidney injury, glomerulonephritis, renal replacement therapy
COVID-19 therapeutic options
Authors:
prof. dr hab. n. med. Krzysztof Tomasiewicz
Keywords:
SARS-CoV-2, COVID-19, therapy, remdesivir, monoclonal antibodies, anti-cytokine medication
Pulmonary rehabilitation after COVID-19
Authors:
dr hab. n. med. Adam J. Białas, prof. UM
prof. dr hab. n. med. Piotr Kuna
Keywords:
COVID-19, rehabilitation
Potential in vitro efficacy of cetylpyridinium chloride against SARS-CoV-2
Authors:
dr hab. n. med. Tomasz Dzieciątkowski
Keywords:
coronavirus, SARS-CoV-2, COVID-19, cetylpyridinium chloride
Other issues